We analyzed signaling pathways from chronically activated PDGFRα in primary cell cultures isolated from P3 GBM tumors with the goal to identify PDGFRα activation-dependent therapeutic vulnerabilities. This evidence concerns the gene PDGFRA and glioblastoma.